2024
GLP1R Gene Expression and Kidney Disease Progression
Triozzi J, Yu Z, Giri A, Chen H, Wilson O, Ferolito B, Ikizler T, Akwo E, Robinson-Cohen C, Gaziano J, Cho K, Phillips L, Tao R, Pereira A, Hung A, Muralidhar S, Moser J, Deen J, Tsao P, Gaziano J, Hauser E, Kilbourne A, Matheny M, Oslin D, Churby L, Whitbourne S, Brewer J, Shayan S, Selva L, Pyarajan S, Cho K, DuVall S, Brophy M, Stephens B, Connor T, Argyres D, Assimes T, Hung A, Kranzler H, Aguayo S, Ahuja S, Alexander K, Androulakis X, Balasubramanian P, Ballas Z, Beckham J, Bhushan S, Boyko E, Cohen D, Dellitalia L, Faulk L, Fayad J, Fujii D, Gappy S, Gesek F, Greco J, Godschalk M, Gress T, Gupta S, Gutierrez S, Harley J, Hamner M, Hurley R, Iruvanti P, Jacono F, Jhala D, Kinlay S, Landry M, Liang P, Liangpunsakul S, Lichy J, Mahan C, Marrache R, Mastorides S, Mattocks K, Meyer P, Moorman J, Morgan T, Murdoch M, Norton J, Okusaga O, Oursler K, Poon S, Rauchman M, Servatius R, Sharma S, Smith R, Sriram P, Strollo P, Tandon N, Villareal G, Walsh J, Wells J, Whittle J, Whooley M, Wilson P, Xu J, Yeh S, Bast E, Dryden G, Hogan D, Joshi S, Lo T, Morales P, Naik E, Ong M, Petrakis I, Rai A, Yen A. GLP1R Gene Expression and Kidney Disease Progression. JAMA Network Open 2024, 7: e2440286. PMID: 39453656, DOI: 10.1001/jamanetworkopen.2024.40286.Peer-Reviewed Original ResearchConceptsGenetic association studiesKidney disease progressionRisk of kidney disease progressionVeterans Affairs Million Veteran ProgramAssociation studiesGenetic risk scoreMillion Veteran ProgramGLP-1RAsDisease progressionIncident end-stage kidney diseaseBody mass indexGlycemic controlGene expressionVeteran ProgramObesity statusMain OutcomesUnadjusted modelsGlucagon-like peptide 1 receptor agonistsStudy participantsPeptide 1 receptor agonistsAbsence of diabetesMass indexMedian follow-upRisk scoreGenotype-Tissue Expression project
2010
SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals
Esterlis I, Cosgrove KP, Petrakis IL, McKee SA, Bois F, Krantzler E, Stiklus SM, Perry EB, Tamagnan GD, Seibyl JP, Krystal JH, Staley JK. SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals. Drug And Alcohol Dependence 2010, 108: 146-150. PMID: 20074869, PMCID: PMC2871672, DOI: 10.1016/j.drugalcdep.2009.12.006.Peer-Reviewed Original ResearchConceptsDrinks/occasionNicotinic acetylcholine receptorsControl nonsmokersAcetylcholine receptorsHeavy drinkersHeavy drinkingLast alcoholic beverageHeavy alcohol drinkersHeavy alcoholSingle photon emissionSeverity of drinkingEffect of ageTobacco smokingAlcohol drinkersAlcohol drinkingCommon neural substrateNonsmokersAlcohol consumptionReceptor availabilityLarger studyAlcohol drinksAlcohol use behaviorsAddictive disordersDrinkersNeural substrates
2001
Contingency Management Interventions: From Research to Practice
Petry N, Petrakis I, Trevisan L, Wiredu G, Boutros N, Martin B, Kosten T. Contingency Management Interventions: From Research to Practice. American Journal Of Psychiatry 2001, 158: 694-702. PMID: 11329388, DOI: 10.1176/appi.ajp.158.5.694.Peer-Reviewed Original Research
2000
Similarities in the Disturbances in Cortical Information Processing in Alcoholism and Aging: A Pilot Evoked Potential Study
Boutros N, Reid M, Petrakis I, Campbell D, Torello M, Krystal J. Similarities in the Disturbances in Cortical Information Processing in Alcoholism and Aging: A Pilot Evoked Potential Study. International Psychogeriatrics 2000, 12: 513-525. PMID: 11263717, DOI: 10.1017/s1041610200006621.Peer-Reviewed Original ResearchConceptsInformation processingCortical information processingSensory gatingPaired-click paradigmOlder healthy subjectsAlcohol dependenceSensory gating deficitsStimulus classificationNovel stimuliOddball paradigmHealthy individualsYoung healthy groupEvoked potential studiesDSM-IV criteriaPotential studiesHealthy subjectsGender-matched groupAged healthy individualsGender-matched healthy individualsGating deficitsMiddle-aged individualsPsychotic symptomsOlder groupProcessingAlcoholic patientsCocaine use and the mid-latency auditory evoked responses
Boutros N, Campbell D, Petrakis I, Krystal J, Caporale M, Kosten T. Cocaine use and the mid-latency auditory evoked responses. Psychiatry Research 2000, 96: 117-126. PMID: 11063784, DOI: 10.1016/s0165-1781(00)00207-9.Peer-Reviewed Original ResearchConceptsCocaine-dependent subjectsInter-stimulus intervalMid-latency auditoryAge-matched healthy control subjectsCocaine useHealthy control subjectsDifferent inter-stimulus intervalsChronic cocaine useLong inter-stimulus intervalsPaired-click paradigmControl subjectsP50 componentN100 componentSignificant decreaseSubjectsAuditoryResponse paradigmSex Differences in Self-Reported and Physiological Response to Oral Cocaine and Placebo in Humans
Singha A, McCance-Katz E, Petrakis I, Kosten T, Oliveto A. Sex Differences in Self-Reported and Physiological Response to Oral Cocaine and Placebo in Humans. The American Journal Of Drug And Alcohol Abuse 2000, 26: 643-657. PMID: 11097197, DOI: 10.1081/ada-100101900.Peer-Reviewed Original ResearchConceptsBad drug effectsSex differencesSystolic blood pressureCocaine-abusing volunteersGreater increasePentobarbital-ChlorpromazineBlood pressurePlacebo controlDrug effectsActive drugOral cocainePlaceboBaseline ratingsCocaineGreater ratingsMalesDrugsFemalesPhysiological responsesResponseAlcohol groupDifferencesVolunteers
1999
CSF Monoamine Metabolite and Beta Endorphin Levels in Recently Detoxified Alcoholics and Healthy Controls: Prediction of Alcohol Cue‐Induced Craving?
Petrakis I, Trevisan L, D'Souza C, Gil R, Krasnicki S, Webb E, Heninger G, Cooney N, Krystal J. CSF Monoamine Metabolite and Beta Endorphin Levels in Recently Detoxified Alcoholics and Healthy Controls: Prediction of Alcohol Cue‐Induced Craving? Alcohol Clinical And Experimental Research 1999, 23: 1336-1341. PMID: 10470976, DOI: 10.1111/j.1530-0277.1999.tb04355.x.Peer-Reviewed Original ResearchConceptsAlcohol-dependent patientsHealthy controlsEndorphin levelsCSF levelsMonoamine metabolitesCSF measuresHealthy subjectsNorepinephrine metabolite MHPGLower CSF levelsBeta-endorphin levelsEarly-onset patientsCerebrospinal fluid levelsLate-onset patientsCentral neurotransmitter systemsCSF monoamine metabolitesDopamine metabolite HVAAlcohol cue exposureAlcohol-dependent individualsCue-Induced CravingAlcohol cue reactivityLumbar punctureMetabolite HVANeurotransmitter systemsMonoaminergic dysregulationMetabolite MHPG
1998
Naltrexone Augmentation of Neuroleptics in Schizophrenia
Sernyak M, Glazer W, Heninger G, Charney D, Woods S, Petrakis I, Krystal J, Price L. Naltrexone Augmentation of Neuroleptics in Schizophrenia. Journal Of Clinical Psychopharmacology 1998, 18: 248-251.. PMID: 9617985, DOI: 10.1097/00004714-199806000-00011.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScaleTotal BPRS scoreBPRS scoresNegative symptomsAddition of naltrexoneBPRS subscale scoresOngoing neuroleptic treatmentSingle-blind basisPlacebo-controlled trialSingle-blind fashionSubscale scoresBPRS total scorePsychiatric Rating ScaleDSM-III criteriaSubsequent treatmentRepeated-measures analysisNaltrexone augmentationNeuroleptic medicinesNeuroleptic regimenTransient exacerbationPlacebo armNeuroleptic treatmentClinical benefitRepeated-measures ANOVANaltrexone
1997
Effect of alpha-methyl-para-tyrosine on response to cocaine challenge
Stine S, Krystal J, Petrakis I, Jatlow P, Heninger G, Kosten T, Chamey D. Effect of alpha-methyl-para-tyrosine on response to cocaine challenge. Biological Psychiatry 1997, 42: 181-190. PMID: 9232210, DOI: 10.1016/s0006-3223(96)00331-9.Peer-Reviewed Original ResearchConceptsDopamine metabolite homovanillic acidCocaine-induced euphoriaNorepinephrine metabolite 3Placebo-controlled studyBlood pressure responseMetabolite homovanillic acidReduced plasma levelsTyrosine hydroxylase inhibitorSerum cocaine levelsTuberoinfundibular dopamine systemAMPT pretreatmentAcute reductionIntranasal administrationPara-tyrosinePlasma levelsProlactin levelsCocaine challengeHomovanillic acidCatecholamine synthesisHeart rateHydroxylase inhibitorAlpha-methylDopamine systemCocaine levelsTherapeutic potential